The global parenteral nutrition market size is calculated at USD 7.22 billion in 2024, grew to USD 7.67 billion in 2025, and is predicted to hit around USD 13.17 billion by 2034, poised to grow at a CAGR of 6.2% between 2024 and 2034. The North America parenteral nutrition market size accounted for USD 2.96 billion in 2024 and is anticipated to grow at the fastest CAGR of 6.33% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Parenteral Nutrition Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Parenteral Nutrition Market Revenue and Volume Forecast, by Nutrient Type, 2024-2034
8.1.1. Carbohydrates
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Parenteral Lipid Emulsion
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Single Dose Amino Acid Solution
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Trace Elements
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Vitamins & Minerals
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Parenteral Nutrition Market Revenue and Volume Forecast, by Stage Type, 2024-2034
9.1.1. Adult
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Pediatrics
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Parenteral Nutrition Market Revenue and Volume Forecast, by Indication, 2024-2034
10.1.1. Alzheimer’s
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Nutrition Deficiency
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Cancer Care
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Chronic Kidney Diseases
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1.5. Orphan Diseases
10.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1.6. Dysphagia
10.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Volume Forecast (2021-2034)
10.1.8. Malabsorption/GI Disorder/Diarrhea
10.1.8.1. Market Revenue and Volume Forecast (2021-2034)
10.1.9. Others
10.1.9.1. Market Revenue and Volume Forecast (2021-2034)
11.1. Parenteral Nutrition Market Revenue and Volume Forecast, by Sales Channel, 2024-2034
11.1.1. Online Sales
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Retail Sales
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Institutional Sales
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.1.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.2.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.3.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.4.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Nutrient Type (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, by Stage Type (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Indication (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by Sales Channel (2021-2034)
13.1. Baxter
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Allergan
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Actavis Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Otsuka Pharmaceutical Factory, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Grifols, S.A.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. B. Braun Melsungen AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Vifor Pharma
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Fresenius Kabi AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sichuan Kelun Pharmaceutical Co., Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc. (Hospira Inc.)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample